Article thumbnail

Molecular Mechanism and Potential Targets for Blocking HPV-Induced Lesion Development

By E. Guzmán-Olea, V. H. Bermúdez-Morales, O. Peralta-Zaragoza, K. Torres-Poveda and V. Madrid-Marina


Persistent infection with high-risk HPV is the etiologic agent associated with the development of cervical cancer (CC) development. However, environmental, social, epidemiological, genetic, and host factors may have a joint influence on the risk of disease progression. Cervical lesions caused by HPV infection can be removed naturally by the host immune response and only a small percentage may progress to cancer; thus, the immune response is essential for the control of precursor lesions and CC. We present a review of recent research on the molecular mechanisms that allow HPV-infected cells to evade immune surveillance and potential targets of molecular therapy to inhibit tumor immune escape

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1999). A human papillomavirus E2 transcriptional activator: the interactions with cellular splicing factors and potential function in pre-mRNA processing,”
  2. (2006). A l c o c e r - G o n z ´
  3. A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity,” Cancer ImmunologyImmunotherapy,vol.49,no.7,pp.347–360,2000.
  4. (2005). A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions,”
  5. (2006). Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAILmediated apoptosis,”
  6. (1996). Acti- vation of the endogenous p53 growth in- hibitory pathway in HeLa cervical carci- noma cells by expression of the bovine papillomavirus E2 gene,”
  7. (2011). AlcocerGonz´ a l e z ,J .M o r e n o ,a n dV .M a d r i d - M a r i n a ,“ I L - 1 0e x p r e s -sion is regulated by HPV E2 protein in cervical cancer cells,”
  8. (2001). An abundant class of tiny RNAs with probable regulatory roles in
  9. (2001). An extensive class of small RNAs in
  10. and E7 oncoproteins from human papillomavirus type 16 induce activation of human transforming growth factor β1 promoter throughout Sp1 recognition sequence,”ViralImmunology,vol.19,no.3,pp.468–480,2006.
  11. (2001). andT.Tuschl,“Duplexes of21-nucleotideRNAsmediateRNA interference in cultured mammalian cells,”
  12. (1998). Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway,”
  13. (1998). Bid,aBcl2interactingprotein,mediatescytochromecrelease from mitochondria in response to activation of cell surface death receptors,”
  14. (2008). Correlation between IL-10 gene expression and HPV infection in cervical cancer: a mechanism for immune response escape,”
  15. (1998). Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression,”
  16. (1997). Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection,”
  17. (2004). Cytokines in cancer pathogenesis and cancer therapy,”
  18. (1999). D eG r u i j l ,H .J .B o n t k e s ,A .J .C .V a nd e nM u y s e n b e r g et al., “Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix,”
  19. (2003). D o e n c h ,C .P .P e t e r s e n ,a n dP .A .S h a r p ,“ s i R N A sc a n function as miRNAs,”
  20. (2007). Differential expression of T-cell CD3-zeta chains in patients with cervical dysplasia before and after treatment,” InternationalJournalofGynecologicalCancer,v ol.17,no .6,pp .
  21. (2001). Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response,”
  22. (2003). Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells,”
  23. (2006). Eri et al., “Intratumor injection of small interfering RNA-targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer ,”
  24. (2004). Escape from immunotherapy: possible mechanisms that influence tumor regression/progression,”
  25. (1999). Expression of CD3-ζ on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes,”
  26. (1997). Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis,”
  27. (2009). Flores-Sosa et al., “CD3ζ expression and T cell proliferation are inhibited by TGF-β1 and IL-10 in cervical cancer patients,”
  28. (2001). Functional anatomy of siRNAs for mediating efficientRNAiinDrosophilamelanogasterembryolysate,”The
  29. (2001). G a b r i l o v i c h ,M .P .V e l d e r s ,E .M .S o t o m a y o r ,a n dW .M . Kast, “Mechanism of immune dysfunction in cancer mediated
  30. (2004). Gel-based application of siRNA to human epithelial cancer cells induces RNAidependentapoptosis,”Oligonucleotides,vol.14,no.4,pp.239– 248,
  31. (2010). Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-γ-dependent responseagainstB16F10-Nex2melanoma,”CancerGeneTherapy,
  32. (1994). Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas is related to the retention of E1/E2 genes,”
  33. (2009). Guzm´ anOlea et al., “HPV 16 E2 protein induces apoptosis in human and murine HPV 16 transformed epithelial cells and has antitumoral effects in vivo,” Tumor Biology,v o l .3 0 ,n o .2 ,p p .
  34. (1993). Human interleukin10 can directly inhibit
  35. (2006). Human papillomavirus and cervical cancer: burden of illness and basis for prevention,”
  36. (2000). Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus,”
  37. (2007). Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses,”
  38. (2001). Identification of novel genes coding for small expressed RNAs,”
  39. (1991). IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells,”
  40. (1991). IL-10 inhibits cytokine production by activated macrophages,”
  41. (1995). IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response,”
  42. (1991). IL-10: a novel cytotoxic T cell differentiation factor,”
  43. (2007). Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia,”
  44. (2006). Immune responses to human papillomavirus,”
  45. (2004). Importance of IL-10 for CTLA-4-Mediated Inhibition of Tumor-Eradicating Immunity,”
  46. (2003). In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA,”
  47. (2000). Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral
  48. (1998). Inhibition of Bak-induced apoptosis by
  49. Inhibition of interleukin-10 (IL-10) production fromMOPC315tumorcellsbyIL-10antisenseoligodeoxynucleotides enhances cell-mediated immune responses,” Cancer ImmunologyImmunotherapy,vol.49,no.8,pp.433–440,2000.
  50. (1991). Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigenpresenting capacity of monocytes via downregulation of class II major histocompatibility complex expression,”
  51. (1990). Interleukin 10, a novel B cell stimulatory factor:
  52. (1997). Interleukin-10 is a growth factor for human melanoma cells and downregulates HLA class-I, HLA class-II and ICAM-1 molecules,”
  53. (2010). Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth,”
  54. (2002). Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation,”
  55. (2007). Interleukin-12: biological properties and clinical application,”
  56. (2005). Interleukin10 and the immune response against cancer: a counterpoint,”
  57. (1999). Interleukin12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity,”
  58. (2008). K.Yamato,T.Yamada,M.Kizakietal.,“Newhighlypotentand specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer,”
  59. (2009). Katakam et al., “Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity,”
  60. (1990). M a c N e i l ,T .S u d a ,K .W .M o o r e ,T .R .M o s m a n n ,a n d A. Zlotnik, “IL-10, a novel growth cofactor for mature and immature T cells,”
  61. (2003). Mikyskov´ a et al., “Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: effects of CBM-4A potentiated with
  62. (2010). Modulation of apoptosis by early human papillomavirus proteins in cervical cancer,”
  63. (2006). Natural history of papillomavirus infections,”
  64. oncogene expression by RNA interference in vitro and in vivo,”
  65. (2001). Pathogenesis of esophageal squamous cell carcinoma with lymphoid stroma,”
  66. (1998). Potentiation of E7 antisense RNA-induced antitumor immunity by co-delivery of
  67. (2001). Predominant Th2/Tc2 polarity of tumorinfiltrating lymphocytes in human cervical cancer,”
  68. (2002). Reversal of tumorinduced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody,”
  69. (2008). RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53,”
  70. (2005). RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin,”
  71. (2002). Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of
  72. (2000). Serum interleukin10 is an independent prognos-tic factor in advanced solid tumors,”
  73. (1993). Settleman et al., “Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene,”
  74. (2011). Silencing of HPV16 E6 and E7 oncogenic activities by small interference RNA induces autophagy and apoptosis in human cervicalcancercells,”
  75. (2003). siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells,”
  76. (1987). Structural and transcriptional analysis of human papilloma- virus type 16 sequences in cervical carcinoma cell lines,”
  77. (1995). Suppression of cellular proliferation by the papillomavirus E2 protein,”
  78. The BPV1-E2 trans-acting protein can be either an activator or a repressor of the HPV18 regulatory region,”
  79. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53,”
  80. (2000). The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway,”
  81. (2004). The human papillomavirus 16 E6 protein binds to Fas-associated deathdomainandprotectscellsfromFas-triggeredapoptosis,”
  82. (2002). The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis,”
  83. (2003). The regulatory E2 proteins of human genital papillomaviruses are pro-apoptotic,”
  84. (2011). The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis,”
  85. (2003). Transcription-independent triggering of the extrinsic pathway of apoptosis by human papillomavirus 18 E2 protein,”
  86. tumor associated macrophages suppress antitumor T cell responses,”
  87. (1992). Tumor immunology: the first century,”
  88. (2001). Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix,”
  89. (2008). u ,L .P u t r a l ,a n dN .M c M i l l a n ,“
  90. (2005). V.H.Berm´ udez-Morales,O.Peralta-Zaragoza,andV.MadridMarina,“Genetherapywithcytokines againstcervical cancer,”
  91. (2003). W.S.Ahn,S.M.Bae,T.Y.Kimetal.,“Atherapymodalityusing recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model,”

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.